Return to Results

Studying Interventions for Managing Patients With Chronic Myeloid Leukemia (CML) in Chronic Phase: The 5-Year Prospective Cohort Study (SIMPLICITY)

new search

Trial Conditions
  • Chronic Myeloid Leukemia
What is the purpose of this trial?

The purpose of this study is to better understand the use of tyrosine kinase inhibitors (TKI) in patients newly diagnosed with CML and their quality of life in a real-world setting.

Date & Status

Recruiting

Who can Participate?

Eligibility

Ages:
18 and older

Gender:
Both

Eligibility

Inclusion Criteria:

- Newly-diagnosed CP-CML patients

- 18 years or older at time of diagnosis

- Receiving treatment with one of the following TKI's for first-line treatment:

a) Imatinib

- Retrospective Imatinib patients who started their first-line Imatinib treatment
between January 2, 2008 and September 30, 2010

- Patients who started their first-line Imatinib treatment on or after October 1, 2010

b) Dasatinib

- Patients who started their first-line Dasatinib treatment after the drug was approved
in this indication

c) Nilotinib

- Patients who started their first-line Nilotinib treatment after the drug was approved
in this indication. Receiving treatment at medical practice (eg. community-based,
office-based, hospital-based, academic setting, oncology center)

Exclusion Criteria:

- Patients who are participating in a clinical trial for CML treatment will be excluded

Gender: Both
Steward Physician(s)
  • Bristol-Myers Squibb
Physician Researcher

Investigator Name:

  • Bristol-Myers Squibb

Other Information

Sponsor: Bristol-Myers Squibb
Phase: N/A
Trial ID: NCT01244750
Volunteers:  Not Accepting Healthy Volunteers

new search

Connect with Steward

Visit Our Twitter Feed Visit Our Facebook Page Email This Page Print This Page

Subscribe to our patient e-newsletter

Copyright © 2014 Steward Health Care
Connect Healthcare Panacea CMS Solutions